Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

L. Pilotte, P. Larrieu, V. Stroobant, D. Colau, E. Dolušić, R. Frédérick, E. De Plaen, C. Uyttenhove, J. Wouters, B. Masereel, B.J. Van Den Eynde

Résultats de recherche: Contribution à un journal/une revueArticleRevue par des pairs

57 Téléchargements (Pure)

Résumé

Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance, and IDO1 inhibition is an active area of drug development. Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. Here, we show that enzymatically active TDO is expressed in a significant proportion of human tumors. In a preclinical model, TDO expression by tumors prevented their rejection by immunized mice. We developed a TDO inhibitor, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors. Our results describe a mechanism of tumoral immune resistance based on TDO expression and establish proof-of-concept for the use of TDO inhibitors in cancer therapy.
langue originaleAnglais
Pages (de - à)2497-2502
Nombre de pages6
journalProceedings of the National Academy of Sciences of the United States of America
Volume109
Numéro de publication7
Les DOIs
Etat de la publicationPublié - 14 févr. 2012

Empreinte digitale Examiner les sujets de recherche de « Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation